Is subclinical hypothyroidism associated with hyperhomocysteinemia?

Endocrine Practice

Volumn 10, Issue 5, 2004, Pages 399-403

  Aldasouqi, Saleh ^a   Nkansa Dwamena, David ^a   Bokhari, Samia ^a   Alzahrani, Ali S ^b   Khan, Murthaza ^a   Al Reffi, Amal ^a   Merdad, Amal ^a  

^a KING FAHD ARMED FORCES HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHYROIDISM; MALE; MIDDLE AGED; RISK FACTOR;

ADULT; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPOTHYROIDISM; MALE; MIDDLE AGED; RISK FACTORS;

EID: 17144382106     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.5.399     Document Type: Article

References (50)

1. Nedrebø B, Ericsson UB, Nygard O, et al. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism. 1998;47:89-93.
2. Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann Intern Med. 1999;131:348-351.
3. Lien EA, Nedrebø BG, Varghaug JE, Nygard O, Aavkvaag A, Ueland PM. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metab. 2000;85:1049-1053.
4. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis. 2001;155:195-201.
5. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270-278.
6. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
7. Nedrebø BG, Nygard O, Ueland PM, Lien EA. Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment. Clin Chem. 2001;47:1738-1741.
8. Diekman MJ, van der Put NM, Blom HJ, Tijssen JG, Wiersinga WM. Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism. Clin Endocrinol (Oxf). 2001;54:197-204.
9. Fokkema MR, Weijer JM, Dijck-Brouwer DA, van Doormaal JJ, Muskiet FA. Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults. Clin Chem. 2001;47:1001-1007.
10. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
11. De Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002;54:599-618.
12. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
13. Feiner AS. Homocyst(e)ine and cardiovascular disease [letter]. Ann Intern Med. 2000;132:676.
14. Cooper DS. Clinical practice: subclinical hypothyroidism. N Engl J Med. 2001;345:260-265.
15. McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab. 2001;86:4585-4590.
16. Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab. 2001;86:4591-4599.
17. Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism: effect of levothyroxine therapy. Arch Intern Med. 1990;150:2097-2100.
18. Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein( a) in subclinical hypothyroidism. Clin Endocrinol (Oxf). 1995;43:445-449.
19. Ross D. Subclinical hypothyroidism. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid. 6th ed. Philadelphia, PA: JB Lippincott, 1991: 1256-1262.
20. Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab. 2001;86:1206-1211.
21. Franklyn J. "Subclinical hypothyroidism": to treat or not to treat, that is the question. Clin Endocrinol (Oxf). 1995;43:443-444.
22. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534.
23. Burman KD. Is long-term levothyroxine therapy safe? Arch Intern Med. 1990;150:2010-2013.
24. Caron P, Calazel C, Parra HJ, Hoff M, Louvet JP. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of L-thyroxine therapy. Clin Endocrinol (Oxf). 1990;33:519-523.
25. Engler H, Riesen WF. Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem. 1993;39:2466-2469.
26. Meier C, Staub JJ, Guglielmetti M, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (The Basel Thyroid Study). J Clin Endocrinol Metab. 2001;86:4860-4866.
27. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf). 1996;44:643-649.
28. Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure; a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993-3001.
29. Gheri RG, Colli E, Mansani R, Brandi ML. Subclinical hyperthyroidism and hypothyroidism [article in Italian]. Recenti Prog Med. 2000;91:588-593.
30. Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid. 2002;12:421-425.
31. Deicher R, Vierhapper H. Homocysteine: a risk factor for cardiovascular disease in subclinical hypothyroidism? Thyroid. 2002;12:733-736.
32. Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003;166:379-386.
33. Andrees M, Boran G, Clarke G, Connor GO. Homocysteine in subclinical hypothyroidism, a risk factor for atherosclerosis [abstract]. Poster presentation at: The British Endocrine Societies Meeting, March 2003, Glasgow, Scotland. Poster P 280.
34. Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol in persons with "high-normal" TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol. 1998;138:141-145.
35. Vatten LJ, Refsum H, Nygard O, et al. tHCY, established risk factors, and cardiovascular mortality: the Hordaland Homocysteine Study [abstract]. J Inherit Metab Dis. 2003;26(Suppl 1):24.
36. Barbé F, Klein M, Chango A, et al. Homocysteine, folate, vitamin B12, and transcobalamins in patients undergoing successive hypo- and hyperthyroid states [letter]. J Clin Endocrinol Metab. 2001;86:1845-1846.
37. Naurath HJ. Hyperhomocysteinemia in advanced age. Clin Chem Lab Med. 2001;39:695-697.
38. Stehouwer CD. Heterogeneity of the association between plasma homocysteine and atherothrombotic disease: insights from studies of vascular structure and function. Clin Chem Lab Med. 2001;39:705-709.
39. Troughton JA, Woodside JV, Young IS, et al (on behalf of the PRIME Investigators). Homocysteine and cardiovascular risk: the PRIME Study [abstract]. J Inherit Metab Dis. 2003;26(Suppl 1):5.
40. Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocysteinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med. 2001;161:1589-1594.
41. de Jong S. Hyperhomocysteinaemia in patients with peripheral arterial occlusive disease. Clin Chem Lab Med. 2001;39:714-716.
42. Bertsch T, Mielke O, Höly S, et al. Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy. Clin Chem Lab Med. 2001;39:721-724.
43. Stanger O, Weger M, Renner W, Konetschny R. Vascular dysfunction in hyperhomocyst(e)inemia: implications for atherothrombotic disease. Clin Chem Lab Med. 2001;39:725-733.
44. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem. 1993;39:263-271.
45. Lavie L, Perelman A, Lavie P. Plasma homocysteine levels in obstructive sleep apnea: association with cardiovascular morbidity. Chest. 2001;120:900-908.
46. Green R, Chong YY, Jacobsen DW, Robinson K, Gupta M. Serum homocysteine is high in hypothyroidism: a possible link with coronary artery disease. Ir J Med Sci. 1995;164(Suppl 15):27-28.
47. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med. 2001;39:666-674.
48. den Heijer M, Keijzer MB. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med. 2001;39:710-713.
49. Kado D, Karlamangla A, Selhub J, et al. Plasma total homocysteine, folate, B vitamins, and cognitive function in older high functioning adults: MacArthur Studies of Successful Aging [abstract]. J Inherit Metab Dis. 2003; 26(Suppl 1):6.
50. Weiss D. Hyperhomocysteinemia in hypothyroidism [letter]. Ann Intern Med. 2000;132:677.